TTI-622 is a type of protein called a fusion protein, which is similar to an antibody. It is designed to target and block a protein called CD47. CD47 is present on cancer cells, and is used by cancer cells to hide from your body’s immune system.
|Developed By||Trillium Therapeutics, Inc, a Pfizer company|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.
SparkCures is working closely with Trillium Therapeutics, Inc, a Pfizer company to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners